An inch wide and a mile deep—that’s the sort of expertise CSO of Artios Pharma, Dr. Graeme Smith, brings his benchtop. Since his time at Cambridge, Smith has been laser focused on DDR mechanisms, first elucidating, and then translating those observations to create the PARP inhibitor drug, Lynparza. Developed at Kudos Pharma, and later, AstraZeneca, hear Smith recall his “aha” moment for this first-in-class blockbuster drug, as well as his descriptions of his two new DDR-targeting, clinical stage assets developed at Artios that leverage his knowledge of novel DDR pathways—including those that will overcome resistance to PARP inhibition.